Status of vaccine research and development for enterotoxigenic Escherichia coli

Vaccine

Volumn 34, Issue 26, 2016, Pages 2880-2886

  Bourgeois, A Louis ^a   Wierzba, Thomas F ^a   Walker, Richard I ^a  

^a PATH   (United States)

Author keywords

Adjuvants; Combined vaccines; Diarrheal disease; Enteric vaccines; Enterotoxigenic Escherichia coli (ETEC); Impact assessments

Indexed keywords

CHOLERA VACCINE; ESCHERICHIA COLI VACCINE; IMMUNOGLOBULIN A ANTIBODY; SECRETORY IMMUNOGLOBULIN; TOXOID; SUBUNIT VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CAMPYLOBACTER; CELLULAR IMMUNITY; CHOLERA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; ENTEROPATHY; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSPOT ASSAY; ESCHERICHIA COLI INFECTION; HUMAN; IMMUNOGENICITY; INTESTINE INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN SUBUNIT; SALMONELLA; SHIGELLA; SOCIOECONOMICS; CLINICAL TRIAL (TOPIC); ESCHERICHIA COLI INFECTIONS; MEDICAL RESEARCH; MICROBIOLOGY; TRENDS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DIARRHEA; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; HUMANS; VACCINES, SUBUNIT;

EID: 84962487828     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.076     Document Type: Article

References (51)

1. Svennerholm A.M., Tobias J. Vaccines against enterotoxigenic Escherichia coli. Expert Rev Vaccines 2008, 7(6):795-804.
2. Zhang W., Sack D.A. Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines 2012, 11(6):677-694.
3. Kotloff K.L., Nataro J.P., Blackwelder W.C., Nasrin D., Farag T.H., Panchalingam S., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective case-control study. Lancet 2013, 382(9888):209-222.
4. Platts-Mills J.A., Babji S., Bodhidatta L., Gratz J., Haque R., Havt A., et al. Pathogen-specific burdens of community diarrhea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 2015, 3:e564-e575.
5. Kosek M., Haque R., Lima A., Babji S., Shrestha S., Qureshi S., et al. Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth faltering. Am J Trop Med Hyg 2013, 88(2):390-396.
6. Liu J., Kabir F., Manneh J., Lertsethtakarn P., Begum S., Gratz J., et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicenter study. Lancet Infect Dis 2014, 14:716-724.
7. Lozano R., Naghavio M., Foremen K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age-groups in 1990 and 2010: a systematics analysis for the global burden of disease study 2010. Lancet 2012, 380:2095-2128.
8. Lanata C., Fischer-Walker C., Olascoaga A.C., Torres C.X., Aryee M.J., Black R.E., et al. Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS Negl Trop Dis 2013, 8(1):1-11.
9. Lamberti L.M., Bourgeois A.L., Fischer-Walker C.L., Black R.E., Sack D. Estimating diarrheal illness and death attributable to Shigellae and enterotoxigenic Escherichia coli among older children, adolescents and adults in South Asia and Africa. PLoS Negl Trop Dis 2014, 8(2):e2705.
10. Murray C.L., Lozano T.R., Naghavi M., Flaxman A.D., Michaud C., Ezzati M., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2197-2223.
11. Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2163-2196.
12. Halverson H.A., Schlett C.D., Riddle M.S. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006, 101(8):1894-1899.
13. Dupont H.L., Ericsson C.D., Farthing M.J. Expert review of evidence base for preventions of traveler's diarrhea. J Travel Med 2009, 16(3):149-160.
14. Read L.T., Hahn R.W., Thompson C.C., Bauer D.L., Norton E.B., Clements J.D. Simultaneous exposure to Escherichia coli heat-labile and heat-stable enterotoxins increases fluid secretion and alter cyclic nucleotide and cytokine production by intestinal epithelial cells. Infect Immun 2014, 82:5308-5316.
15. Verbrugghe E., Van Parys A., Leyman B., Boyen F., Arnouts S., Lundberg U., et al. Heat-labile enterotoxin of Escherichia coli promotes intestinal colonization of Salmonella enterica. Comp Immunol Microbiol Infect Dis 2015, 43:1-7.
16. Glenn G.M., Francis D.H., Danielsen E.M. Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines. Infect Immun 2009, 77:5206-5215.
17. Riddle M.S., Savarino S.J. Moving beyond a heat-labile enterotoxin-based vaccine against enterotoxigenic Escherichia coli. Lancet Infect Dis 2014, 14:174-175.
18. Peltola H., Siitonen A., Kyrönseppä H., Simula I., Mattila L., Oksanen P., et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991, 338:1285-1289.
19. Walker R.I. An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children. Vaccine 2015, 33:954-965.
20. Behrens R.H., Cramer J.P., Jelinek H., Shaw H., von Sonnenburg F., Wilbraham D., et al. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travelers' diarrhea: a phase 3, randomized, double-blind; placebo controlled field trial in travel from Europe to Mexico and Guatemala. Lancet Infect Dis 2014, 197-205.
21. Fleckenstein J.M., Sheikh A., Qadri F. Novel antigens for enterotoxigenic Escherichia coli vaccines. Expert Rev Vaccines 2014, 13(5):631-639.
22. Taxt A.M., Diaz Y., Bacle A., Grauffel C., Reuter N., Aasland R., et al. Characterization of immunological cross-reactivity between enterotoxigenic Escherichia coli heat-stable toxin and human guanylin and uroguanylin. Infect Immun 2014, 82:2913-2922.
23. Ruan X., Robertson D.C., Nataro J.P., Clements J.D., Zhang W., STa Toxoid Vaccine Consortium Group Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing anti-STa antibodies. Infect Immun 2014, 82:1823-1832.
24. Rheingans R., Latyner L., Amaya M., Atherly D. Potential contribution of nutritional and long-term outcomes on the cost-effectiveness of enterotoxigenic Escherichia coli and Shigella vaccination. Presented at the 8th international conference on vaccines for enteric diseases 2015.
25. Porter C., Pecenka C., Rheingans R., Riddle M., Laytner L., Amaya M., et al. Cost-effectiveness of traveler's diarrhea vaccination. Presented at the 8th international conference on vaccines for enteric diseases 2015.
26. Fischer Walker C.L., Walker N. The Lives Saved Tool (LiST) as a model for diarrhea mortality reduction. BMC Med 2014, 12:1-13.
27. Steffen R., Castelli F., Nothdurft H.D., Rombo L., Zuckerman N.J. Vaccination against enterotoxigenic Escherichia coli, a cause Traveler's diarrhea. J Travel Med 2005, 12:102-107.
28. PATH, BIO Ventures for Global Health The case for investment in enterotoxigenic Escherichia coli vaccines 2011, Seattle, WA.
29. Qadri F., Saha A., Tanvir A., Al Tarique A., Begum Y.A., Svennerholm A.M. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Infect Immun 2007, 75:3961-3968.
30. Harro C., Chakraborty S., Feller A., DeNearing B., Cage A., Ram M., et al. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol 2011, 18(10):1719-1727.
31. Levine M.M., Nalin D.R., Hoover D.L., Bergquist E.J., Hornick R.B., Young C.R. Immunity to enterotoxigenic Escherichia coli. Infect Immun 1979, 23:729-736.
32. Porter C.K., Riddle M.S., Tribble D.R. A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). Vaccine 2011, 29:5869-5885.
33. Darsley M., Harro C., Chakraborty S., Sack D., DeNearing B., Bourgeois A.L., et al. DmLT adjuvanted live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine candidate protects against virulent ETEC in a human ETEC challenge model. Presented at the 8th international conference on vaccines for enteric diseases 2015.
34. Sack D.A., Shimko J., Torres O., Bourgeois A.L., Francia D.S., Gustafsson B., et al. Randomized, double-blind, safety and efficacy of a killed oral vaccine for enteroxigenic E. coli diarrhoea of travelers to Guatemala and Mexico. Vaccine 2007, 25:4392-4400.
35. Walker R.I., Clifford A. Recommendations regarding the development of combined enterotoxigenic Escherichia coli and Shigella vaccines for infants. Vaccine 2014, 33:946-953.
36. Naylor C., Lu M., Haque R., Mondal D., Buonomo E., Nayak U., et al. Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. EBioMedicine 2015, 2:1759-1766.
37. Isidean S.D., Riddle M.S., Savarino S.J., Porter C.K. A systematic review of ETEC epidemiology focusing on colonization factor and toxin-expression. Vaccine 2011, 29:6167-6178.
38. Vilchez S., Becker-Dreps S., Amaya E., Perez C., Paniagua M., Reyes D., et al. Characterization of enterotoxigenic Escherichia coli strains isolated from Nicaraguan children in hospital, primary care and community settings. J Med Microbiol 2014, 63:729-734.
39. Torres O.R., Gonzalez W., Lemus O., Pratdesaba R.A., Matute J.A., Wiklund G., et al. Toxins and virulence factors of enterotoxigenic Escherichia coli associated with strains isolated from indigenous children and international visitors to a rural community in Guatemala. Epidemiol Infect 2015, 143:1662-1671.
40. Freedman D.J., Tacket C.O., Delehanty A., Maneval D.R., Nataro J., Crabb J.H. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic Escherichia coli. J Infect Dis 1998, 177:662-667.
41. Shirley D.A., McArthur M.A. The utility of human challenge studies in vaccine development: lessons learned from cholera. Vaccine 2011, 1:3-13.
42. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007, 25:3684-3691.
43. Steele D., Riddle M., Van De Verg L., Bourgeois A.L. Vaccine for enteric diseases: a meeting summary. Expert Rev Vaccines 2012, 11:407-409.
44. Lundgren A., Bourgeois A.L., Carlin N., Clements J., Gustafsson B., Hartford M., et al. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized placebo-controlled Phase I study. Vaccine 2014, 32:7077-7084.
45. Roy K., Hamilton D.J., Fleckenstein J.M. Cooperative role of antibodies against heat-labile toxin and the EtpA adhesin in preventing toxin delivery and intestinal colonization by enterotoxigenic Escherichia coli. Clin Vaccine Immunol 2012, 19:1603-1608.
46. Bhuiyan T.R., Lundin S.B., Khan A.T., Lundgren A., Harris J.B., Calderwood S.B., et al. Cholera caused by V. cholerae O1 induces T cell responses in the circulation. Infect Immun 2009, 77:1888-1893.
47. Laird R., Gutierrez R., Savarino S.J., Riddle M., Maciel M. Phenotypic and functional evaluation of T cell responses after intradermal immunization with LTR192G, an attenuated form of the enterotoxigenic E. coli (ETEC) labile toxin (LT), as an adjuvant for an ETEC vaccine. Presented at the American association of immunologist annual mtg 2014.
48. Lundgren A., Cardeno A., Kaim J., Svennerholm A.M. T-cell responses to an oral inactivated multivalent ETEC vaccine. Presented at the 8th international conference on vaccines for enteric diseases 2015.
49. Harro C., Gutierrez R., Talaat K., Porter C., Riddle M., Maciel M., et al. Protective efficacy of an enterotoxigenic E. coli fimbrial tip adhesin vaccine given with LTR192G by intradermal vaccination against experimental challenge with CFA/I-ETEC in adult volunteers. Presented at the 3rd skin vaccination summit 2015.
50. Future directions for research on enterotoxigenic Escherichia coli vaccines in developing countries. WHO Wkly Epidemiol Rec 2006, 81(11):97-104.
51. Murray C.J.L., Barber R.M., Foremen K.J., Ozgoren A.A., Abd-Allah F., Abera S.F., et al. Global, regional and national disability-adjusted life years (DALYS) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015, 386:2145-2191.